Carlos Pérez, MD, The University of Texas Health Science Center at Houston, Houston, TX, discusses an exploratory analysis of the impact of race and ethnicity on disease modifying treatment (DMT) use and sociodemographic and clinical characteristics in patients with multiple sclerosis (MS). Despite having a greater risk of disability, minority population enrollment in MS clinical trials is low, raising questions of the generalizability of treatment efficacy evidence to these populations. The study compared DMT use and disease characteristics between Hispanic, African American and Caucasian patients with MS. Similar DMT class use was seen across the 3 groups. However, evidence suggests there may be differential responses to treatment and tolerability profiles in different cohorts. This interview took place during the ACTRIMS Forum 2021.